Dyadic Intl Inc Del - DYAI STOCK NEWS

Dyadic International (NASDAQ: DYAI) announced its Q2 2024 financial results and recent company progress. Key highlights include:

• Entered a development and commercialization partnership with Proliant Health and Biologicals for animal-free recombinant albumin products
• Joined a development agreement with a Top 10 global dairy company for non-animal alpha-lactalbumin
• Provided samples of C1-produced avian influenza 'Bird Flu' antigen for potential use in poultry and cattle vaccines
• Demonstrated strong immune response in animal studies for C1-produced H5 Clade 2.3.3.4.b A/Astrakhan recombinant ferritin nanoparticle vaccine candidate
• Cash and investment grade securities of $10.1 million as of June 30, 2024
• Q2 2024 revenue decreased to $386,000 from $837,000 in Q2 2023
• Net loss for Q2 2024 was $2,045,000 or $(0.07) per share

Dyadic International, Inc. (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein production for vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming second quarter 2024 financial results release and corporate update conference call. The event is scheduled for Tuesday, August 13, 2024, at 5:00 p.m. Eastern Time.

Investors and interested parties can access the call via toll-free (877-407-0784) or international (+1-201-689-8560) numbers, using the Conference ID: 13743569. A webcast will also be available, with an archive accessible on Dyadic's Investor Relations website within 24 hours after the live event. Participants are encouraged to submit questions for the Q&A session via email to ir@dyadic.com prior to the call.

Dyadic International (NASDAQ: DYAI) has announced a strategic partnership with Proliant Health and Biologicals to develop and commercialize recombinant albumin products.

Under the agreement, Dyadic will receive an upfront milestone payment of $1.5 million and a share of the profits from PHB's sales of animal-free recombinant albumin, made using Dyadic's microbial platforms. The partnership aims to launch its first product in the first half of 2025, targeting the $6 billion serum albumin market.

Dyadic's COO, Joe Hazelton, highlighted the partnership as a strategic move to generate revenue in the Alternative Proteins segment, leveraging Dyadic's protein production technology and PHB's market presence. PHB's CEO, Chris Detzel, emphasized the growing demand for alternative protein sources and the partnership's potential for product innovation in the life sciences industry.

Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale production of proteins for vaccines, therapeutics, and other applications, announced its participation in several industry events in June 2024.

These events include BIO 2024 at the San Diego Convention Center from June 3-6, where Dyadic will present on June 5 at 11:00 AM PT. Additionally, Dyadic will attend the Future Food Tech-Alt Proteins conference in Chicago from June 17-18, and the 2024 NIIMBL National Meeting in Washington, DC from June 25-27.

These appearances are part of Dyadic's strategy to engage with industry stakeholders and showcase their innovations. Meetings can be scheduled with Dyadic's management by contacting Heidi Zosiak.

Dyadic International (NASDAQ: DYAI) released its Q1 2024 results, reporting a net loss of $2.01 million or $(0.07) per share, compared to a net loss of $0.96 million or $(0.03) per share a year ago. Revenue for the quarter decreased to $335,000 from $934,000 in Q1 2023. Cash and equivalents stood at $12.1 million as of March 31, 2024.

Key advancements include positive Phase 1 results for DYAI-100, a COVID-19 booster vaccine, and multiple collaborations on vaccine and antibody projects. The company also expanded its work in animal health and alternative proteins sectors.

Strategic partnerships were formed to develop rabies vaccines and alternative proteins. The financial standing was bolstered by a $6.0 million convertible note. Leadership changes include Patrick Lucy as Board Chairman and Joe Hazelton as COO.

Dyadic International, a biotechnology company, will be attending several industry and investor events in May 2024. The events include PEGS Boston, EFHutton Annual Global Conference, ECI Vaccine Technology IX, and Lytham Spring 2024 Investor Conference. Management members will be present to discuss the company's innovative microbial platforms and biopharmaceutical products.

Dyadic International, Inc. will report its financial results for the first quarter of 2024 and host a corporate update conference call on May 14, 2024. The company focuses on large-scale protein manufacture for vaccines, therapeutics, and non-pharmaceutical applications.

Dyadic International, Inc. announced the closing of a $6.0 million convertible note in a private placement. They reported positive topline data from a Phase 1 trial for their COVID-19 vaccine candidate, DYAI-100. Dyadic also entered into multiple fully funded vaccine and antibody projects, executed a term sheet for microbial protein production, and announced strategic partnerships for rabies prophylactics and bio-threat solutions. They expanded collaborations with various organizations and published preclinical studies. The company highlighted financial results, board changes, and upcoming conference calls.

Dyadic International, Inc. announces changes in board leadership with Michael Tarnok stepping down as Chairman and Patrick Lucy appointed as his successor. Dr. Barry Buckland retires, reducing the Board size. Joseph Hazelton appointed as Chief Operating Officer. Patrick Lucy brings extensive biotechnology experience and aims to maximize shareholder value.